Triptolide may inhibit osteoclast formation by regulating RANKL/RANK/OPG signal pathway, targeting which with triptolide may, therefore, be an important therapeutic strategy for preventing bone destruction in RA. This evidence concerns the gene TNFRSF11B and rheumatoid arthritis.